BIO-PATH HOLDINGS, INC. Files 8-K
Ticker: BPTH · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: BPTH
TL;DR
BPTH filed an 8-K on 12/19/24, check for updates.
AI Summary
On December 19, 2024, BIO-PATH HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that BIO-PATH HOLDINGS, INC. has submitted a current report to the SEC, which may contain important updates for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently increases risk.
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- December 19, 2024 (date) — Report Date
- 4710 Bellaire Boulevard , Suite 210 , Bellaire , Texas 77401 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for BIO-PATH HOLDINGS, INC.?
The filing is primarily for Regulation FD Disclosure and includes Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on December 19, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is BIO-PATH HOLDINGS, INC.
What is the state of incorporation for BIO-PATH HOLDINGS, INC.?
The state of incorporation is Delaware.
What is the business address of BIO-PATH HOLDINGS, INC.?
The business address is 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-12-19 16:30:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20241219x8k.htm (8-K) — 39KB
- bpth-20241219xex99d1.htm (EX-99.1) — 18KB
- bpth-20241219xex99d1001.jpg (GRAPHIC) — 11KB
- 0001558370-24-016391.txt ( ) — 194KB
- bpth-20241219.xsd (EX-101.SCH) — 3KB
- bpth-20241219_lab.xml (EX-101.LAB) — 16KB
- bpth-20241219_pre.xml (EX-101.PRE) — 10KB
- bpth-20241219x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 19, 2024, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity." A copy of such press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated December 19, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: December 19, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer